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Abstract:  
Introduction: Endovascular cooling is currently used for hypothermia treatment and fever 
reduction therapy. At the same time, little is known about the risks associated to 
endovascular cooling in patients treated with an endovascular cooling catheter (ECC). 
Methods: A retrospective chart review of 122 patients with subarachnoid haemorrhage (SAH) 
treated with an ECC either for therapeutic hypothermia or for fever reduction was performed. 
ECC associated thromboembolic events (TEE) such as pulmonary embolism and thrombosis 
were recorded and compared between patients treated with an ECC and patients treated 
only with a central venous line (CVL). Additionally, various laboratory parameters were 
recorded to determine if they might be related to the frequency of TEE´s.    
Results:  43 Patients were treated with an ECC and 79 with a CVL. Patients in the ECC 
group suffered more frequently from TEE (37%) than those with a CVL (5%). None of the 
laboratory parameters was associated with an increased TEE risk. The treatment with an 
ECC alone was a risk factor for a TEE, independent from age as well as from Hunt and Hess 
grade. 
Conclusion: Our data show that the treatment with ECC increases the risk of TEE in SAH 
patients. Therefore, especially when considered for fever reduction, non-invasive devices for 
surface cooling should be the first choice.  
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Introduction: 
Therapeutic hypothermia has neuroprotective effects in adults after cardiopulmonary 
resuscitation [1]. Fever has been identified as a risk factor for poor outcome in patients with 
ischemic stroke [2] subarachnoid hemorrhage (SAH) [3], intracerebral hemorrhage [4] or 
traumatic brain injury [5]. 
For targeted, long-term temperature control, endovascularly based systems might have 
several advantages concerning efficacy and usability compared to surface cooling [6, 7]. The 
need for a central venous line, however, calls for an adequate risk assessment and 
evaluation of potential complications such as thromboembolic events (TEE), as these might 
be promoted by the long-term application of the device. Up to date, only small case series of 
patients with traumatic brain injury are described concerning this specific complication [8]. 
The aim of the present study was to analyze the incidence of TEE in a large cohort of 
patients with aneurysmal subarachnoid hemorrhage (SAH) treated with endovascular cooling 
catheters (ECC) compared to SAH patients treated with conventional central venous lines 
(CVL) and to identify potential risk factors. 
 
Methods: 
The study was approved by the ethics committee of the University Hospital of Zurich. A 
retrospective chart review was performed including all patients with aneurysmal SAH 
admitted to the Neurosurgical Intensive Care Unit of the University Hospital Zurich between 
January 2011 and March 2013 and treated with ECC for fever reduction or therapeutic 
hypothermia. Patients with a severe concomitant disease were excluded from the analysis. 
Indications for hypothermia treatment were brain edema with intracranial hypertension and/or 
symptomatic cerebral vasospasm refractory to conventional treatment. The correspondent 
treatment algorithms are previously described [9]. The following parameters were analysed: 
patient’s clinical state at admission by means of Hunt and Hess scale, type of catheter (CVL 
or ECC), date of catheter insertion and removal. Deep venous thrombosis (DVT) was 
evaluated by sonography if the patient showed any clinical signs of swelling, pain, elevated 
skin temperature or red/livid colour of the skin at the extremity in which the catheter was 
inserted or by screening in patients with suspected high risk for TEE. Pulmonary embolism 
was diagnosed with contrast-enhanced CT scan if the patient showed any symptoms or 
incidentally. The following daily measured parameters were analysed in the ECC group: 
fibrinogen, C reactive protein (CRP), procalcitonin C (PTC), leucocyte and thrombocyte 
counts. Vena cava filter were inserted because of DVT and coexistent strict contraindication 
for anticoagulation. 
ECCs were changed routinely every 5 days or earlier if signs of infection occurred. CVLs 
were changed only with clinical signs of infection. Every patient’s individual, continuous ECC 
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application period, from start until end of the treatment period (application from only one up 
to several catheters), was combined to one consecutive treatment event. If the continuous 
ECC treatment was interrupted for any reason, the patient was excluded from the study. The 
day of TEE diagnosis after ECC onset was recorded (provided the patient was still 
hospitalized in our department) irrespectively of whether the TEE occurred during the ECC 
application period or afterwards. If a patient suffered from more than one TEE, only the first 
one was considered the index event. From all TEE the median day of occurrence was 
calculated. This determined median day was applied to compare the above cited laboratory 
parameters in the ECC patients with TEE to those in patients without TEE. In both groups the 
laboratory parameters collected from the median day and the 4 preceding days were 
averaged. Prophylaxis against TEE was routinely performed with pneumatic stockings in 
combination with unfractionated heparin 5000 E/24h cont. i.v. started 6 hours after aneurysm 
clipping or aneurysm coiling.  
The endovascular cooling system applied was a dual infusion lumen 8.5F 20-cm catheter 
(Cool Line Catheter, Zoll Medical, California, USA). This catheter is furnished with an 
additional lumen, which ends in two balloons (sized 55 mm in length and 5×5 mm in 
diameter). The balloons are perfused with a sterile Ringer’s lactate solution via a closed-loop 
tubing system. The tubing system is connected to a temperature-management device 
(Coolgard System, Zoll Medical, California, USA), consisting of a temperature adjustable 
water bath (0.5 °C–42 °C) depending on the patient’s own temperature [9]. Conventional 
CVL with 4- or 5- lumen (Arrow International Inc., Teleflex, Durham, NC, USA) were applied 
in all patients. 
 
Statistical analysis: Patient characteristics, as well as fibrinogen, leucocyte, thrombocyte 
count, CRP, PCT values and severity (Hunt and Hess grade) were compared using Mann-
Whitney-U test. Binominal variables were compared between the groups by the chi-square 
test or Fisher’s exact test where appropriate. A value of p<0.05 was regarded as statistically 
significant. Bivariate logistic regressions were used to test the predictive power of treatment 
with ECC for development of TEE independently of age and Hunt and Hess grade. 
Calibration of the models was assessed using the Hosmer-Lemeshow test. Odds ratios (OR) 
were reported with 95% confidence intervals (CI). Full multiple logistic regressions were not 
performed because of the small number of events. IBM SPSS Statistics 21.0, Armonk, NY 
was used. 
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Results 
A total of 122 patients with (SAH) was analyzed. 117 patients suffered from aneurysmal, 5 
from non-aneurysmal SAH. Mean age of the patient population was 57.1 ± 12.2 years, 
severity grade according to Hunt and Hess was in mean 2.9 ± 1.3. Endovascular cooling 
catheters (ECC) were applied in 43 patients, either for fever treatment (22 patients) or 
therapeutic hypothermia (21 patients). During the same time period, 79 patients were not 
treated with ECCs and used as control group. In these patients only CVL were routinely 
applied. All ECCs were inserted into the femoral vein, whereas CVLs were inserted either in 
the subclavian (69 cases) or jugular vein (10 cases). Patients in the ECC group (53.1 ± 9.7 
years) were younger than those in the CVL group (59.3 ± 12.9, p = 0.004). With 3.6 ± 1.2 the 
Hunt and Hess grade in the ECC group was higher than in the CVL group with 2.5 ± 1.2 (p < 
0.001). Overall 20 patients (16%) died. Among them, 12 patients died under withdrawal of 
treatment due to brain herniation and/or multiple infarctions, 7 patients died with the signs of 
multiorgan failure due to sepsis syndrome and 1 because of a rebleeding. Mortality in 
patients with ECC was higher (14 among 43; 33%) compared to those with CVL (6 among 
79; 8%; p < 0.001). There was no significant difference in mortality between patients treated 
for fever (6 among 21; 29%) compared to those treated with hypothermia (9 among 22; 
41%). 
Patients in the ECC group suffered more frequently from TEE (37%) than those with CVL 
(5%) (p < 0.001) (table 1). Thrombosis, confirmed by sonography, occurred more frequently 
in the ECC group (26%) compared to the CVL group (5%) (p < 0.001). Thrombosis occurred 
significantly more frequently in patients treated for fever (52%) than in patients treated with 
hypothermia (23%) (p = 0.044). Pulmonary embolism, confirmed with contrast-enhanced CT 
scan, occurred in 5 patients of the ECC group and in 2 patients of the CVL group (p = 0.039). 
Pulmonary embolism tended to occur more frequently in patients treated for fever, although 
without statistical significance. Because of strict contraindication for anticoagulation, 6 
patients, all in the ECC group treated for fever were protected against pulmonary embolism 
with cava filters inserted into the inferior caval vein. All of them were on prophylaxis with 
heparin. 
The treatment with ECC alone was a risk factor for TEE independent from age (OR 12.5, 
95% CI 3.6 – 43.5); p < 0.001) as well as from Hunt and Hess grade (OR 8.9, 95% CI 2.5 -
31.25; p = 0.001). 
The median day for the occurrence of TEE was day 15. In 32 patients of the ECC group, 
median values for fibrinogen, leucocyte, thrombocyte counts, CRP and PCT could be 
calculated for day 11 to 15 (table 2). There were no significant differences between the 
values of fibrinogen, leucocyte, CRP and PCT between patients treated with hypothermia or 
for fever, but patients with fever had a higher thrombocyte count than those treated with 
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hypothermia (p = 0.022). There were no significant differences between the values of 
patients with and patients without TEE. 
 
 
Discussion 
To our knowledge, this is the first study of a large cohort of intensive care patients who were 
treated with ECC and followed for the occurrence of TEE. In a small cohort group of patients 
(n=11) with traumatic head injury and treated with ECC, Simosa et al. found a DVT incidence 
of 50% [8]. 
In this study, we found a significantly higher risk for developing a TEE in ECC patients (37%) 
compared to the control group (5%). In a large register study of more than 15,000 patients 
with aneurismal SAH or intracerebral hemorrhage, Kshettry et al. found a general incidence 
of 4% for TEE. Unfortunately, they didn´t report their results with respect to the type of 
catheters used. [11]. In our study, there was also a significantly increased risk for TEE in 
ECC patients treated for fever compared to those treated with therapeutic hypothermia. This 
may be due to a generally higher TEE risk in patients with an infection [12], although only the 
thrombocyte count and no other infection parameter was higher in fever patients compared 
to those treated with therapeutic hypothermia. In the study population of Kshettry et al, 
infectious complications were a significant risk factor to suffer from TEE. 
Pulmonary embolism occurred more frequently in ECC patients (12%) compared to patients 
who had only a CVL (3%).  Kshettry reported in their study population a pulmonary embolism 
incidence of 1%. Several limitations of the study have to be considered: The robustness of 
the results is limited. For multiple logistic regression analyses, the patient number was too 
small. The mortality, furthermore, in the ECC group was higher than in the control group. 
This was probably due to the fact that the severity grade in patients of the ECC group was 
higher. Further studies have to distinguish if the TEE risk is also increased in patients with 
other diseases than SAH treated with endovascular cooling catheters.  
The higher incidence of TEE in the ECC group, might have been influenced by the central 
venous access site. A recent Cochrane analysis showed that the incidence of thrombotic 
complications is as high as 22% with femoral central venous access routes, compared to 
subclavian catheters with only 1.9%, whereas no significant differences exist between 
femoral and jugular catheters [13]. In the present series, all ECCs were inserted into the 
femoral vein, whereas most CVLs were inserted in the subclavian vein. The risk for TEE for 
ECC inserted in the subclavian vein should be examined exclusively. Moreover, in a future 
prospective study it is recommended to perform routine screening Doppler examinations to 
detect asymptomatic TEE as well. 
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Conclusion: 
Our data show that treatment with ECC increases the risk of TEE in SAH patients. Therefore, 
especially for fever control, non-invasive devices for surface cooling should be the first 
choice.  
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Table 1: Incidence of thrombosis, pulmonary embolism and installed Cava filters  
 
 
Table 2: Labor parameters analyzed. Values are given as median for day 11 – 15 after ECC 
onset and range 
 
 
Conflict of interest: Achim Müller, Andreas Lorenz, Burkhardt Seifert and Emanuela Keller 
declare that they have no conflict of interest. 
 All 
patients 
(n=122) 
Patients with 
central venous 
lines 
(n = 79) 
Patients with endovascular cooling 
catheters 
(n = 43) 
   All 
(n = 43) 
Treated for 
fever 
(n = 21) 
Treated with 
hypothermia 
(n = 22) 
Thrombosis 
and  
pulmonary 
embolism 
confirmed by 
sonography  
and/or CT 
scan 
20 (16%) 4 (5%)  16 (37%) 11 (52%) 5 (23%) 
Thrombosis 
confirmed by 
sonography 
15 (12%) 4 (5%) 11 (26%) 7 (32%) 4 (19%) 
Pulmonary 
embolism 
confirmed by 
CT scan 
7 (6%) 2 (3%) 5 (12%) 4 (19%) 1 (5%) 
Cava filter 
installed 
6 (5%) 0 (0%) 6 (14%) 6 (27%) 0 (0%) 
 Fibrinogen 
median for 
day  11-15 
(g/l) 
Leucocyte 
count median 
for day 11-15 
(G/l) 
Thrombocyte 
count median 
for day 11-15 
(G/l) 
CRP median 
for day 11-
15 (ng/l) 
PCT median 
for day 11-
15 (ug/l) 
All   
(n=32) 
 
6.0 
(3.6-14.6) 
9.33 
(2.9-19.3) 
193 
(85-859) 
53 
(2-388) 
0.16 
(0.01-5.57) 
Fever  (n=17) 
 
6.1 
(4.8-17) 
9.39 
(2.94-17) 
253
(134-859) 
65 
(15-388) 
0.16 
(0.05-5.57) 
Hypothermia (n=15) 
 
5.6  
(3.6-13) 
9.28 
(6.2-16.7) 
152 
(85-459) 
44 
(2.2-250) 
0.16 
(0.01-0.62) 
Thrombosis (n=15) 
 
5.7 
(3.6-14.6) 
9.44 
(2.94-16.82) 
253 
(97-522) 
65 
(2.2-388) 
0.15 
(0.03-5.57) 
No thrombosis (n=17) 
 
6.3 
(4.1-13) 
9.06 
(5.28-19.33) 
186 
(85-859) 
47 
(15-250) 
0.19 
(0.01-0.62) 
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